Maurice Steenhuis

Dr. Maurice Steenhuis

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
WHWillianne Hoepel
Willianne Hoepel
HCHung-Jen Chen
Hung-Jen Chen
CGChiara E. Geyer
Chiara E. Geyer
SASona Allahverdiyeva
Sona Allahverdiyeva
XMXue D. Manz
Xue D. Manz
JDJeroen den Dunnen
Jeroen den Dunnen
High titers and low fucosylation of human anti–spike protein IgG promote alveolar macrophage activation and inflammation.

28 May 2021 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
PDF file
MSMaurice Steenhuis
Maurice Steenhuis
PUPeter van Ulsen
Peter van Ulsen
NMNathaniel I Martin
Nathaniel I Martin
JLJoen Luirink
Joen Luirink
Gram-negative pathogens are a rapidly increasing threat to human health worldwide due to high rates of antibiotic resistance and the lack of development of novel antibiotics. The protective cell envelope of gram-negative bacteria is a major permeability barrier that contributes to the problem by restricting the uptake of antibiotics. On the other hand, its unique architecture also makes it a suitable target for antibiotic interference. In particular, essential multiprotein machines that are required for biogenesis of the outer membrane have attracted attention in antibacterial design strategies. Recently, significant progress has been made in the development of inhibitors of the β-barrel assembly machine (BAM) complex. Here, we summarize the current state of drug development efforts targeting the BAM complex in pursuit of new antibiotics.

14 June 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
MSMaurice Steenhuis
Maurice Steenhuis
FCFederico Corona
Federico Corona
CHCorinne M. Ten Hagen-Jongman
Corinne M. Ten Hagen-Jongman
WVWaldemar Vollmer
Waldemar Vollmer
DLDominique Lambin
Dominique Lambin
JLJoen Luirink
Joen Luirink
The development of new antibiotics is particularly problematic in Gram-negative bacteria due to the presence of the outer membrane (OM), which serves as a permeability barrier. Recently, the β-barrel assembly machine (BAM), located in the OM and responsible for β-barrel type OM protein (OMP) assembly, has been validated as a novel target for antibiotics. Here, we identified potential BAM complex inhibitors using a screening approach that reports on cell envelope σE and Rcs stress in Escherichia coli. Screening a library consisting of 316 953 compounds yielded five compounds that induced σE and Rcs stress responses, while not inducing the intracellular heat-shock response. Two of the five compounds (compounds 2 and 14) showed the characteristics of known BAM complex inhibitors: synergy with OMP biogenesis mutants, decrease in the abundance of various OMPs, and loss of OM integrity. Importantly, compound 2 also inhibited BAM-dependent OMP folding in an in vitro refolding assay using purified BAM complex reconstituted in proteoliposomes.

13 November 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
MSMaurice Steenhuis
Maurice Steenhuis
CHCorinne M. Ten Hagen-Jongman
Corinne M. Ten Hagen-Jongman
JUJP van Ulsen
JP van Ulsen
JLJoen Luirink
Joen Luirink
The structural integrity of the Gram-negative cell envelope is guarded by several stress responses, such as the σE, Cpx and Rcs systems. Here, we report on assays that monitor these responses in E. coli upon addition of antibacterial compounds. Interestingly, compromised peptidoglycan synthesis, outer membrane biogenesis and LPS integrity predominantly activated the Rcs response, which we developed into a robust HTS (high-throughput screening) assay that is suited for phenotypic compound screening. Furthermore, by interrogating all three cell envelope stress reporters, and a reporter for the cytosolic heat-shock response as control, we found that inhibitors of specific envelope targets induce stress reporter profiles that are distinct in quality, amplitude and kinetics. Finally, we show that by using a host strain with a more permeable outer membrane, large-scaffold antibiotics can also be identified by the reporter assays. Together, the data suggest that stress profiling is a useful first filter for HTS aimed at inhibitors of cell envelope processes.

28 February 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PBPim Bouwmans
Pim Bouwmans
RMReshwan Malahe
Reshwan Malahe
AMA. Lianne Messchendorp
A. Lianne Messchendorp
PVPriya Vart
Priya Vart
CICéline Imhof
Céline Imhof
MHMarc H. Hemmelder
Marc H. Hemmelder
The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease. A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4-G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition. 216 CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17-1.78)], p<0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per ten-fold increase in antibody level after vaccination (aOR 0.82 [0.70-0.96], p=0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61-8.25], p=0.003). CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.

5 April 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
LBLaura Boekel
Laura Boekel
FHFemke Hooijberg
Femke Hooijberg
EVErik H Vogelzang
Erik H Vogelzang
YBYaëlle R Besten
Yaëlle R Besten
MLMaureen Leeuw
Maureen Leeuw
GWGertjan Wolbink
Gertjan Wolbink
Background Research on the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term prospective data on the development of SARS-CoV-2 antibodies in these patients are lacking. Methods Adult patients with rheumatic IMIDs from the Amsterdam Rheumatology and Immunology Center, Amsterdam were invited to participate. All patients were asked to recruit their own sex-matched and age-matched control subject. Clinical data were collected via online questionnaires (at baseline, and after 1–4 and 5–9 months of follow-up). Serum samples were collected twice and analysed for the presence of SARS-CoV-2-specific antibodies. Subsequently, IgG titres were quantified in samples with a positive test result. Findings In total, 3080 consecutive patients and 1102 controls with comparable age and sex distribution were included for analyses. Patients were more frequently hospitalised compared with controls when infected with SARS-CoV-2; 7% vs 0.7% (adjusted OR: 7.33, 95% CI: 0.96 to 55.77). Only treatment with B-cell targeting therapy was independently associated with an increased risk of COVID-19-related hospitalisation (adjusted OR: 14.62, 95% CI: 2.31 to 92.39). IgG antibody titres were higher in hospitalised compared with non-hospitalised patients, and slowly declined with time in similar patterns for patients in all treatment subgroups and controls. Interpretation We observed that patients with rheumatic IMIDs, especially those treated with B-cell targeting therapy, were more likely to be hospitalised when infected with SARS-CoV-2. Treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs other than B-cell targeting agents is unlikely to have negative effects on the development of long-lasting humoral immunity against SARS-CoV-2.